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The human immunodeficiency virus type 1 (HIV-1) nucleocapsid p7 (NCp7) protein holds two highly conserved
“CCHC” zinc finger domains that are required for several phases of viral replication. Basic residues flank the zinc
fingers, and both determinants are required for high-affinity binding to RNA. Several compounds were previously
found to target NCp7 by reacting with the sulfhydryl group of cysteine residues from the zinc fingers. Here, we have
identified an N,N-bis(1,2,3-thiadiazol-5-yl)benzene-1,2-diamine (NV038) that efficiently blocks the replication of a
wide spectrum of HIV-1, HIV-2, and simian immunodeficiency virus (SIV) strains. Time-of-addition experiments
indicate that NV038 interferes with a step of the viral replication cycle following the viral entry but preceding or
coinciding with the early reverse transcription reaction, pointing toward an interaction with the nucleocapsid
protein p7. In fact, in vitro, NV038 efficiently depletes zinc from NCp7, which is paralleled by the inhibition of the
NCp7-induced destabilization of cTAR (complementary DNA sequence of TAR). A chemical model suggests that the
two carbonyl oxygens of the esters in this compound are involved in the chelation of the Zn2 ion. This compound
thus acts via a different mechanism than the previously reported zinc ejectors, as its structural features do not allow
an acyl transfer to Cys or a thiol-disulfide interchange. This new lead and the mechanistic study presented provide
insight into the design of a future generation of anti-NCp7 compounds.
Human immunodeficiency virus type 1 (HIV-1) is the caus-
ative agent of AIDS and still represents a serious global public
health problem. Shortly after the isolation of the virus, an
intensive search for compounds that would inhibit the infec-
tivity and replication of the virus was initiated. Although in the
last 25 years, 25 compounds were licensed for the treatment of
AIDS, and significant progress has been made in the treatment
of HIV-infected individuals, there is presently no curative
treatment for HIV/AIDS. Although established anti-HIV
treatments are relatively effective, they are sometimes poorly
tolerated, highlighting the need for a further refinement of
existing antiviral drugs and the development of drugs with
other mechanisms of antiviral action.
In order to replicate, HIV has to undergo several major
steps. First, infectious virions bind to the cellular receptors on
the surface of susceptible cells. The fusion of the viral envelope
with the cellular membrane ensues, and the viral core pene-
trates into the cytoplasm (11). The single-stranded RNA ge-
nome of the virus is copied into a double-stranded linear DNA
molecule by the viral enzyme reverse transcriptase (RT) as-
sisted by nucleocapsid molecules in the core structure (13, 28).
The DNA is then transported to the nucleus as a nucleic
acid-protein complex (the preintegration complex [PIC]) and
is integrated into the host cell’s genome by the action of a
second viral enzyme, integrase (IN), assisted by the NC protein
(2). The covalently integrated form of viral DNA, which is
defined as the provirus, serves as the template for transcrip-
tion. Retroviral RNAs are synthesized, processed, and then
transported to the cytoplasm, where they are translated by an
internal ribosome entry site (IRES)-based mechanism (4) to
produce viral proteins. The proteins that form the viral core,
encoded by the gag and pol genes, initially assemble into im-
mature cores together with two copies of the full-length viral
RNA. As these structures bud through the plasma membrane,
they become enveloped by a lipid bilayer from the cell mem-
brane that also harbors the viral Env glycoproteins in the form
of trimers. Coincident with virus assembly and budding, the
viral protease (PR) cleaves the Gag and Gag-Pol precursors to
release the structural core proteins and Pol enzymes in their
final processed forms.
The development of anti-HIV compounds continues to be
very active, and many lead compounds still emerge from initial
antiviral screens. Compounds with a novel mechanism of ac-
tion targeting mutation-intolerant targets are of special inter-
est. The CCHC zinc fingers and the HIV nucleocapsid NCp7
protein are examples of such targets. The zinc finger motif is
essential for virus replication, and the mutation of cysteine
residues, which functions as zinc binding ligands, resulted in
noninfectious virus particles (15, 17, 18), further underlining
the importance of NCp7 in the viral life cycle. Several classes
of compounds targeting the retroviral NCp7 have been de-
scribed, including 3-nitrosobenzamide (NOBA) (30), 2,2-di-
thiobisbenzamide (DIBA) (31), cyclic 2,2-dithiobisbenzamide
(e.g., SRR-SB3) (37), 1,2-dithiane-4,5-diol-1,1-dioxide (29),
azadicarbonamide (ADA) (32), pyridinioalkanoyl thiolesters
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(PATEs) (35), and S-acyl-2-mercaptobenzamide thioesters
(SAMTs) (20). These compounds react with the sulfhydryl
group of cysteine residues from the NCp7 zinc fingers. On the
other hand, zinc chelation by a general zinc chelator, TPEN
[N,N,N,N-tetrakis(2-pyridylmethyl)ethylenediamine], inhib-
its Vif function and enhances the APOBEC3G (A3G)-medi-
ated degradation of HIV; however, this effect is unrelated to
the interaction of Vif with A3G (25, 38). Here we report the
characterization of an N,N-bis(4-ethoxycarbonyl-1,2,3-thiadia-
zol-5-yl)benzene-1,2-diamine (NV038) that efficiently inhibits
the replication of HIV-1, HIV-2, and simian immunodeficiency
virus (SIV). Studies of the mechanism of action indicate that
this compound interferes with an early stage of the replication
cycle coinciding with an early function of the NCp7 protein of
Gag and chelates the Zn2 from NCp7.
MATERIALS AND METHODS
Cells, viruses, and virus-like particles (VLPs). MT-4 and C8166 cells were
grown and maintained in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum, 2 mM L-glutamine, 0.1% sodium bicarbonate, and 20
g gentamicin per ml.
The HIV-1IIIB strain was provided by R. C. Gallo and M. Popovic. The
NL4-3.GFP11 strain expressing an enhanced version of green fluorescent protein
(GFP) in place of Nef was a kind gift of A. Valentin and G. N. Pavlakis (National
Cancer Institute at Frederick, Frederick, MD). For all tests described, the NL4-
3.GFP11 virus was obtained by DNA transfection of 293T cells with the molec-
ular clone. Next, 1 ml of virus-containing supernatant was used to infect 8  106
MT-4 cells in 40 ml of culture medium. Three days after infection, the superna-
tant was collected and used as a viral input in the respective assays.
Vesicular stomatitis virus G protein (VSV-G)-pseudotyped HIV-1 cells con-
taining the envelope glycoprotein of the vesicular stomatitis virus instead of the
wild-type HIV-1 envelope protein were produced by cotransfecting 293T cells
with a NL4.3 molecular clone lacking a functional SUgp120 (pNL4.3-E-GFP)
(39) and a construct encoding VSV-G.
HIV-1 VLPs were generated by the cotransfection of a codon-optimized Gag p55
polyprotein expression plasmid (33) with pVSV-g in 293T cells. These plasmids were
a kind gift of M. Rosati and G. N. Pavlakis (National Cancer Institute at Frederick,
Frederick, MD). To obviate specific cell surface receptor requirements, VLPs were
pseudotyped with the pantropic VSV-G envelope protein.
In vitro antiviral assays. Evaluation of the antiviral activity of the compounds
against HIV-1IIIB in MT-4 cells was performed by using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described (27).
Stock solutions (10 final concentration) of test compounds were added in 25-l
volumes to two series of triplicate wells to allow the simultaneous evaluation of
their effects on mock- and HIV-infected cells at the beginning of each experi-
ment. Serial 5-fold dilutions of test compounds were made directly in flat-
bottomed 96-well microtiter trays using a Biomek 3000 robot (Beckman Instru-
ments, Fullerton, CA). Untreated HIV- and mock-infected cell samples were
included as controls. An HIV-1IIIB stock (50 l) at 100 to 300 50% cell culture
infectious doses (CCID50) or culture medium was added to either the infected or
mock-infected wells of the microtiter tray. Mock-infected cells were used to
evaluate the effects of the test compound on uninfected cells in order to assess
the cytotoxicity of the test compounds. Exponentially growing MT-4 cells were
centrifuged for 5 min at 1,000 rpm, and the supernatant was discarded. The MT-4
cells were resuspended at 6  105 cells/ml, and 50-l volumes were transferred
into the microtiter tray wells. Five days after infection, the viability of mock- and
HIV-infected cells was examined spectrophotometrically by using the MTT as-
say. The MTT assay is based on the reduction of yellow MTT (Acros Organics,
Geel, Belgium) by the mitochondrial dehydrogenase of metabolically active cells
to a blue-purple formazan that can be measured spectrophotometrically. The
absorbances were read in an eight-channel computer-controlled photometer
(Multiscan Ascent reader; Labsystems, Helsinki, Finland) at two wavelengths
(540 and 690 nm). All data were calculated by using the median optical density
(OD) value of three wells. The 50% cytotoxic concentration (CC50) was defined
as the concentration of the test compound that reduced the absorbance (OD at
540 nm [OD540]) of the mock-infected control sample by 50%. The concentra-
tion achieving 50% protection against the cytopathic effect of the virus in in-
fected cells was defined as the 50% effective concentration (EC50).
Evaluation of the antiviral activity of the compounds against NL4-3.GFP11 in
C8166 cells was performed by using flow cytometry (see below), and HIV-1 core
antigen (p24 antigen [Ag]) in the supernatant was analyzed by a p24 Ag enzyme-
linked immunosorbent assay (Perkin-Elmer).
Flow cytometry. Flow cytometric analysis was performed with a FACSCanto II
flow cytometry system (Becton Dickinson, Erembodegem, Belgium) equipped
with a 488-nm argon-ion laser and a 530-nm/30-nm-bandpass filter (FL1, detec-
tion of GFP-associated fluorescence) (Becton Dickinson). Before acquisition,
cells were pelleted at 1,000 rpm for 10 min and fixed in 3% paraformaldehyde
solution. Acquisition was stopped when 10,000 events were counted. Data anal-
ysis was carried out with Cell Quest software (BD Biosciences). Cell debris were
excluded from the analysis by gating on forward- versus side-scatter dot plots.
Time-of-addition experiments. MT-4 cells were infected with HIV-1IIIB at a
multiplicity of infection (MOI) of 0.5. Following a 1-h adsorption period, cells
were distributed into a 96-well tray at 45,000 cells/well and incubated at 37°C.
Test compounds were added at different times (0, 1, 2, 3, 4, 5, 6, 7, 8, 24, and 25 h)
after infection. HIV-1 production was determined at 31 h postinfection via a p24
enzyme-linked immunosorbent assay (Perkin-Elmer, Brussels, Belgium).
Zinc chelation monitored by NPG fluorescence. The zinc chelation assay buffer
consisted of 20 mM HEPES and 10 M ZnCl2 (pH 7.4). Zinc chelation was
monitored by monitoring the decrease in the fluorescence of a zinc-selective
fluorophore, Newport Green (NPG) (Molecular Probes), in the assay buffer at
room temperature. Zinc chelation was initiated by the addition of different
concentrations of test compounds in dimethyl sulfoxide to the zinc chelation
assay buffer and incubation for 20 min at room temperature. An equal volume of
1 M NPG in 20 mM HEPES (pH 7.4) was then added, and the increase
fluorescence was monitored at 530 nm (excitation wavelength  485 nm) by
using the Saffire2 fluorescence reader (Tecan).
Zinc ejection and inhibition of NC(11-55) destabilization of cTAR (comple-
mentary DNA sequence of TAR). The NC(11-55) peptide was synthesized by
solid-phase peptide synthesis on a 433A synthesizer (ABI, Foster City, CA) as
previously described (34). The lyophilized peptide was dissolved in water, and its
concentration was determined by using an extinction coefficient of 5,700
M1  cm1 at 280 nm. Next, 2.5 molar equivalents of ZnSO4 were added to the
peptide, and the pH was raised to its final value by adding buffer. The increase
of pH was done only after the addition of zinc to avoid the oxidization of the
zinc-free peptide.
Doubly labeled cTAR was synthesized at a 0.2 mol scale by IBA GmbH
Nucleic Acids Product Supply (Go¨ttingen, Germany). The 5 terminus of cTAR
was labeled with 6-carboxyrhodamine (Rh6G) via an amino linker with a six-
carbon spacer arm. The 3 terminus of cTAR was labeled with 4-(4-dimethyl-
aminophenylazo)benzoic acid (Dabcyl) using a special solid support with the dye
already attached. Doubly labeled cTAR was purified by reverse-phase high-
performance liquid chromatography (HPLC) and polyacrylamide gel electro-
phoresis. An extinction coefficient at 260 nm of 521,910 M1  cm1 was used for
cTAR. All experiments were performed at 20°C with a solution containing 25
mM Tris-HCl (pH 7.5), 30 mM NaCl, and 0.2 mM MgCl2 (8). Absorption spectra
were recorded with a Cary 400 spectrophotometer. Fluorescence spectra were
recorded at 20°C with a Fluorolog spectrofluorometer (Horiba Jobin-Yvon)
equipped with a thermostated cell compartment. Excitation wavelengths were
295 nm and 520 nm for NC(11-55) and Rh6G-5-cTAR-3-Dabcyl, respectively.
The spectra were corrected for dilution and buffer fluorescence. The protein
spectra were additionally corrected for screening effects due to the zinc-ejecting
agent with the following equation:
IP
Im dp ds dr/2	1 10dp	
dp 1 10dp  ds  dr/2	
where Im is the measured fluorescence of the protein, Ip is the fluorescence
intensity of the protein in the absence of inner filter, dp is the absorbance of the
protein, ds is the absorbance of NV038 at the excitation wavelength, and dr is the
absorbance of NV038 at the emission wavelengths.
RESULTS
Inhibition of HIV and SIV in cell culture. We have discov-
ered an N,N-bis(4-ethoxycarbonyl-1,2,3-thiadiazol-5-yl)benzene-
1,2-diamine (NV038) with anti-HIV and anti-SIV activities in cell
culture (Fig. 1 and Table 1). The inhibition of viral replication was
monitored by measuring the viability of MT-4 cells 5 days after
infection (27). The cytotoxicity of the compound was assessed in
parallel by monitoring the viability of mock-infected cells. Inter-
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estingly, NV038 was equally active against HIV-1IIIB, HIV-2ROD,
and SIVMac251, while compounds lacking the benzenediamine
moiety (NV037) or carrying only one 4-ethoxycarbonyl-1,2,3-thia-
diazyle substitution (NV039) were completely inactive. The well-
characterized nonnucleoside reverse transcriptase inhibitor
(NNRTI) nevirapine did not inhibit the replication of HIV-2 or
SIV at concentrations of up to 7.5 M tested. The 50% cytotoxic
concentration of NV038 was greater than 297.5 M tested, re-
sulting in a selective range value of more than 17.
To assess the potential of NV038 against drug-resistant
HIV-1 strains, its antiviral activity was tested against strains
that are resistant to either the entry antagonist dextran sulfate,
the CXCR4 inhibitor AMD3100, or the NNRTI nevirapine.
NV038 retained its activity against these strains (Table 1),
whereas dextran sulfate, AMD3100, and nevirapine were in-
active against their respective resistant HIV-1 mutants. These
results provide evidences that NV038 does not interfere with
virus-cell (coreceptor) binding or the catalytic reverse tran-
scription activity of viral replication and prompted us to carry
out a more detailed study of the NV038 mechanism of action.
Mechanism-of-action studies: determination of the step in
the virus life cycle affected by the action of NV038. In the
NL4-3.GFP11 molecular clone (36), enhanced GFP (eGFP) is
expressed from multiply spliced nef mRNAs. Therefore, eGFP
expression from this recombinant clone enabled us to deter-
mine whether an inhibitor interferes with a target before or
after the expression of multiply spliced mRNA (12, 12a). To
study the effect of NV038 during a single round of infection,
C8166 cells were infected with NL4-3.GFP11 in the presence
of inhibitors. Cells were harvested 24 h after infection (time
required for a single round of replication), and the number of
eGFP-expressing cells was monitored by flow cytometry (Fig.
2). The toxicity of the compounds was assessed from the for-
ward- versus side-scatter dot plots. As expected, the well-char-
acterized HIV inhibitors dextran sulfate and nevirapine and
the integrase inhibitor L-870,810 caused a dramatic decrease in
numbers of eGFP-expressing cells compared to the untreated
control. In contrast, in cultures treated with the HIV-1 pro-
tease inhibitor ritonavir, the number of eGFP-expressing cells
was similar to that for the untreated control. These results are
consistent with the fact that in a single round of infection,
molecules interfering with a viral component implicated in the
early steps of virus replication inhibit the expression of eGFP,
while molecules targeting a viral component essential for virus
assembly do not inhibit eGFP expression. NV038 behaved like
dextran sulfate, nevirapine, and L-870,810 in that it inhibited
the expression of eGFP (by 94.5% compared to the control),
thus targeting a viral component playing a key role during the
early steps of virus replication.
The above-described results were confirmed when NV038
was evaluated for its inhibitory effect on virus production by
chronically HIV-1-infected HuT-78 cells (data not shown). We
noticed no inhibitory effect on the release of infectious virus at
subtoxic concentrations, while, as expected, the control com-
pound ritonavir, targeting the viral protease, efficiently inhib-
ited the production of infectious viruses. Taken together, such
data suggest that the compound NV038 targets an early viral
function.
Time of drug addition. To identify the viral component tar-
geted by this compound, a time-of-addition experiment was set
up. This experiment determines how long the addition of a
compound can be postponed before its antiviral activity is lost.
Indeed, when an inhibitor that interferes with the binding of
the virus to the host cell is present at the time of virus addition,
FIG. 1. Chemical structures of tested compounds. MW, molecular weight (in thousands).
TABLE 1. Antiviral effect of N,N-bis(4-ethoxycarbonyl-1,2,3-thiadiazol-5-yl)benzene-1,2-diamine and analoguesa
Compound
Mean EC50 
 SEM (M)
Mean CC50 
 SEM
(M)HIV-1IIIB NL4.3/WT
NL4.3/DS5000R
(165-fold)
NL4.3/AMD3100R
(100-fold)
NNRTIRK103N:Y181C
(85-fold) HIV-2ROD SIVMac251
NV037 105 ND ND ND ND 105 ND 105 
 20
NV038 17 
 3 15 
 4.0 10 
 5 8 
 3 4.5 
 0.2 26 
 7 17 
 4 297.5
NV039 290 ND ND ND ND 290 ND 290
a Values are from at least 3 independent experiments. The fold resistance toward the respective inhibitor of resistant strains is given in parentheses (with the EC50
for the NL4.3 wild type WT set as 1). EC50, 50% effective concentration (concentration of inhibitor required for 50% inhibition of viral replication); CC50, 50%
cytotoxic concentration (concentration of inhibitor that kills 50% of the cells); ND, not determined.
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it will inhibit virus replication. However, when this binding
inhibitor is added after virus delivery to the host cell, it will not
interfere with replication. To that end, cells were infected at a
high multiplicity of infection, and either one of the compounds
was added at 1, 2, 3, 4, 5, 6, 7, and 8 h after infection, as
indicated in Fig. 3. Virus replication was monitored by p24
capsid expression at 31 h after infection. Depending on the
drug target, the addition of the compound could be delayed for
hours specifically for each compound without losing its antivi-
ral activity. Dextran sulfate, which interacts with virus adsorp-
tion to the cell, should be added together with the virus (at 0 h)
to be active; its addition at 1 h postinfection or later did not
block viral replication because adsorption had already oc-
curred at this time. For zidovudine (AZT) and nevirapine,
their addition could be delayed for 3 and 4 h postinfection,
respectively. The addition of NV038 could be postponed for
only 1 h, favoring the notion that it targets the incoming core
or the early reverse transcription complex (RTC).
NV038 did not interfere with the virus entry process as
measured with a classical virus-binding assay (data not shown).
The compound also retained full antiretroviral activity against
VSV-G-pseudotyped HIV-1 replication (data not shown), con-
firming that it is not interfering with the specific binding or
fusion processes of HIV-1.
N,N-Bis(4-ethoxycarbonyl-1,2,3-thiadiazol-5-yl)benzene-
1,2-diamine targets one of the Gag proteins. The above-
described data suggest that this new compound interacts with
one or more essential viral components soon after virus entry
into cells. In that respect, NCp7 is a likely candidate since it
plays a critical role in the viral core structure and in DNA
synthesis and maintenance, notably by chaperoning the RT
enzyme during the obligatory minus- and plus-strand DNA
transfers to generate long terminal repeats (LTRs) (13, 21).
To test whether the anti-HIV-1 activity of NV038 is target-
ing one of the Gag proteins (including NCp7), we examined
whether the anti-HIV-1 effect of NV038 could be suppressed
by saturating target cells with HIV-1 virus-like particles
(VLPs) containing Gag and pseudotyped with VSV-G. The
anti-HIV-1 activity of NV038 decreased in the presence of
VLPs, while VLPs had no effect on AMD3100 or on nevirapine
(Fig. 4). These results indicate that the inhibitory effect exhib-
ited by NV038 is saturable and is caused by an interaction with
one or more of the Gag structural proteins.
NCp7, which is one of the Gag proteins, contains two CCHC
zinc fingers required for the specific recognition of genomic
RNA and viral DNA synthesis (reviewed in reference 13).
Using Newport Green (NPG) as a specific zinc indicator, we
have found that N,N-bis(4-ethoxycarbonyl-1,2,3-thiadiazol-5-
FIG. 3. Time-of-addition experiment. MT-4 cells were infected
with HIV-1, and the test compounds were added at different time
points after infection. Virus production was determined by p24 Ag
production in the supernatant at 31 h postinfection. Circles, control;
squares, dextran sulfate (20 M); triangles, AZT (1.9 M); inverted
triangles, nevirapine (7.5 M); crosses, NV038 (297.5 M). This graph
is representative of data for 2 independent experiments.
FIG. 2. NV038 targets a pretranscriptional step of the HIV-1 life
cycle. Cells were infected with NL4-3.GFP11 in the presence of the test
compound, and 24 h after infection, cells were analyzed for GFP expres-
sion as a marker for infection. The amount of GFP-expressing cells (gated
as indicated) were quantified by flow cytometry analysis, and the percent-
age of inhibition of GFP-expressing cells compared to that of the un-
treated control (0%) is given in the upper right corner of each plot.
Concentrations used were as follows: dextran sulfate, 20 M; nevirapine,
7.5 M; L-870,810, 0.3 M; ritonavir, 2.8 M; NV038, 297.5 M.
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yl)benzene-1,2-diamine is able to efficiently chelate zinc (Fig.
5). The assay is based on the increase in Newport Green
fluorescence intensity upon binding Zn2. In this experiment,
NV038 was incubated with 10 M ZnCl2 for 30 min, and free
Zn2 was then quantified by using Newport Green. Figure 5
shows the decrease of Zn2-dependent Newport Green fluo-
rescence in the presence of NV038, suggesting that NV038 is
chelating Zn2 ions. NV037 and NV039 had no effect on
Newport Green fluorescence in the presence of Zn2. Alto-
gether, these experiments provide strong evidence that NV038
is interfering with an early step in viral replication by targeting
HIV-1 NCp7 function and chelating the Zn2 ions from the
zinc fingers.
Zinc ejection and inhibition of NCp7(11-55) destabilization
of cTAR. Zinc ejection from the NCp7 zinc finger by NV038
was monitored through the intrinsic fluorescence of residue
Trp37 of NC(11-55). This residue belongs to the distal zinc
finger motif and shows a 3.0-fold increase of its fluorescence
quantum yield upon zinc binding (9, 24). The addition of a
10-fold excess of NV038 was found to induce a rapid decrease
of Trp37 fluorescence (Fig. 6A), suggesting that NV038 effi-
ciently removes zinc from NC(11-55). After 3 h, the fluores-
cence dropped to a level close to that observed in the presence
of 1 mM EDTA, indicating a nearly full ejection of zinc.
To confirm the zinc ejection, we then monitored, in the
presence of NV038, the NC(11-55)-induced destabilization of
the secondary structure of cTAR DNA (Fig. 6B, inset), the
complementary sequence of the transactivation response ele-
ment, involved in minus-strand DNA transfer during reverse
transcription (3, 5, 8). Indeed, this destabilization is exquisitely
sensitive to the proper folding of the zinc-bound finger motifs
and totally disappears when zinc ions are removed (6). Sensi-
tive monitoring of the NCp7-induced destabilization of cTAR
can be obtained by using the doubly labeled Rh6G-5-cTAR-
3-Dabcyl derivative. In the absence of NC, cTAR is mainly in
a nonfluorescent closed form, where the Rh6G and Dabcyl
labels at the 5 and 3 termini, respectively, of the cTAR stem
are close together, giving excitonic coupling (7). As previously
reported (8), NC(11-55) added to cTAR at a 10-fold molar
excess led to a melting of the bottom of the cTAR stem, which
increases the distance between the two fluorophores and thus
restores Rh6G fluorescence (Fig. 6B). In line with the zinc
ejection hypothesis, the addition of NV038 to the NC(11-55)/
cTAR complex at a molar ratio of 10:1 with respect to NC(11-
55) led to a strong decrease in Rh6G emission and, thus, in
cTAR destabilization. The NC(11-55)-induced destabilization
of cTAR further decreased with time, and the peptide became
almost fully inactive after 3 h of incubation with NV038. More-
over, the loss of the ability of NC(11-55) to destabilize cTAR
was found to closely match the ejection of zinc from the fingers
(Fig. 6C), further confirming that NV038 efficiently removes
bound zinc ions from NCp7.
FIG. 4. NV038 inhibition of HIV-1 NL4-3.GFP11 replication is
decreased in the presence of VLPs expressing the Gag p55 polypro-
tein. Human T-lymphocyte C8166 cells were infected with GFP-en-
coding HIV-1 in the presence or absence of Gag p55-containing VLPs
as indicated. Viral replication in the presence of different concentra-
tions of compound was measured by virus-dependent GFP expression
using flow cytometry.
FIG. 5. Zn2-dependent Newport Green (NPG) fluorescence in
the presence of N,N-bis(1,2,3-thiadiazol-5-yl)benzene-1,2-diamine de-
rivatives. Zinc chelation of the compounds was monitored by measur-
ing the decrease in the fluorescence of the zinc-selective fluorophore
Newport Green.
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DISCUSSION
We have identified N,N-bis(4-ethoxycarbonyl-1,2,3-thiadia-
zol-5-yl)benzene-1,2-diamine (NV038), a new lead compound
that efficiently interferes with the replication of HIV-1, HIV-2,
and SIV and resistant HIV-1 strains. The compound was tested
with different acute and chronic HIV infection models in order
to establish its time of effect and mode of action. Its effective-
ness in inhibiting HIV replication in acute infection models as
opposed to its inability to block virus production from chron-
ically infected cells indicates that the target of NV038 encom-
passes a preintegrational process. Furthermore, time-of-addi-
tion experiments even refined the time of intervention to a
time frame situated after entry and prior to the completion of
the reverse transcription step, indicating that NV038 targets
the incoming core complex. However, compared to the effi-
ciency of AZT or nevirapine, its current EC50 does not predict
sufficient potency for good efficacy in clinical studies. Indeed,
in comparison to these extremely potent inhibitors, the anti-
retroviral activity of NV038 is almost insignificant. However,
one of the keystones of actual anti-HIV treatment, namely, the
phosphonate acyclic nucleotide analogue (R)-PMPA (tenofovir),
has a 50% inhibitory concentration (IC50) of 7 M when assessed
with the same biological system. This is only about half the value
observed for NV038. Nevertheless, its potency might be increased
by chemical modification. By using molecular modeling, a rational
design of new analogues that will enable an improvement of
activity and selectivity is planned.
As NCp7 is one of the possible targets occurring after entry
and prior to the completion of the RT step, the effect of
loading infected cells with an excess of Gag p55 on the inhib-
itory activity of NV038 was tested. The observed loss of the
anti-HIV-1-inhibitory effect of NV038 in the presence of Gag
p55-containing VLPs suggested a stoichiometric interaction of
the compound with a protein derived from Gag p55. In vitro,
we demonstrated that NV038 is able to chelate zinc ions. In-
terestingly, the zinc chelation ability of NV038 and its ana-
logues correlates well with their inhibitory capacity on retro-
viral replication. Indeed, the compound NV038 is able to
chelate zinc and inhibit HIV replication, while the related
compounds NV037 (having a 1,3-proylenediamine linker in-
stead of the 1,2-benzenediamine linker) and NV039 (having
only one 4-ethoxycarbonyl-1,2,3-thiadiazol-5-yl moiety) did not
inhibit HIV in vitro, nor did they chelate zinc. We also dem-
onstrated that NV038 efficiently ejects zinc from NCp7. No-
ticeably, our data (Fig. 6A) indicate that the distal finger motif
releases zinc in the presence of NV038. Moreover, the loss of
the ability of NCp7 to destabilize cTAR was correlated with
the ejection of zinc from the fingers, further confirming that
NV038 efficiently removes the bound zinc ions from NCp7.
FIG. 6. Zn ejection and inhibition of NC(11-55)-promoted cTAR
destabilization by NV038. (A) Ejection of the zinc ions bound to
NC(11-55) by NV038. The emission spectrum of 1 M NCp7 was
recorded either in the absence (diamond) or in the presence of 4.2
g/ml (10 M) NV038 after 1 min (square), 1 h (circle), and 3 h (star)
of incubation. Triangle, emission spectrum of NC(11-55) after the
addition of 1 mM EDTA. (B) Inhibition of NC(11-55)-induced cTAR
destabilization by NV038. The emission spectrum of 0.1 M Rh6G-
5-cTAR-3-Dabcyl was recorded either in the absence (open triangle)
or in the presence of 1 M NC(11-55) before (diamond) and after
incubation with 10 M of the NV038 compound for 1 min (square), 1 h
(circle), and 3 h (star). (Inset) Scheme of the NC(11-55)-induced
destabilization of cTAR and the resulting fluorescence increase of
Rh6G. (C) Correlation between zinc ejection and inhibition of NC(11-
55)-promoted cTAR destabilization. The percentages of Zn2 ejection
(squares) and inhibition of cTAR destabilization (triangles) induced by
10 M NV038 are reported as a function of time. Solid lines represent
double-exponential fits to the data.
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Altogether, these experiments unambiguously pinpoint NCp7
as the target for this new lead compound.
It was reported previously that compounds with zinc ejection
properties can inhibit a postintegration stage of HIV-1 repli-
cation (31). However, the N,N-bis(4-ethoxycarbonyl-1,2,3-
thiadiazol-5-yl)benzene-1,2-diamine described here clearly in-
terferes with an early step happening after viral entry and
before reverse transcription. Other compounds with zinc-eject-
ing properties were previously shown to inhibit an early step of
the HIV-1 life cycle (14). Furthermore, the reported zinc-
ejecting compounds that are interfering with HIV-1 replica-
tion, whether they act on an early or a late stage of the viral life
cycle, have been shown to target one of the functions of the
nucleocapsid (NCp7) protein. Indeed, retroviral nucleocapsid
proteins harbor a multiplicity of functions, including viral RNA
binding and packaging (1, 40), virus infectivity (15, 18), reverse
transcription promotion (16, 19, 22, 26), and the stimulation of
retroviral integration (10). Since these processes are happen-
ing in both early and late stages of the viral life cycle, different
inhibitors targeting different functions of NCp7 could have an
early or a late effect on HIV-1 replication. Further molecular
analysis of how these different classes of NCp7 inhibitors act
and how they structurally interact with NCp7 could be useful to
draw the different functional regions within NCp7 responsible
for early and late functions. At least for the thioester zinc
ejectors, nuclear magnetic resonance (NMR) and mass spec-
troscopy studies showed that they act by the covalent modification
of Cys39 (20). Also, for DIBA compounds, the proposed reaction
mechanism is a thiol-disulfide interchange between DIBA and
NCp7 at Cys36 and Cys49 (23). We speculate that the N,N-
bis(1,2,3-thiadiazol-5-yl)benzene-1,2-diamine described here acts
via a different mechanism, as its structural features do not allow
an acyl transfer to Cys or a thiol-disulfide interchange. Future
research, such as structure-activity relationship experiments, is
needed to confirm this hypothesis. However, the limited series of
compounds reported here already indicates that the anti-HIV
activity is linked to the Zn2-chelating capacity of the compound.
It is likely that the conformation adopted by NV038 is determined
by the chelation of the Zn2 ion by the two carbonyl oxygens of
the esters and furthermore by a hydrogen bond between the NH
and the carbonyl of the esters. This model is depicted in Fig. 7 and
is in agreement with the typical bond lengths for a Zn-oxygen
complex (1.85 Å) and the interatomic distance for N-H…O
(1.95 Å). The selectivity of the compound reveals a possible
specific chelation of zinc at the zinc fingers. This implies that
NV038 harbors structural features that direct the molecule to the
zinc fingers of NCp7. In an ongoing effort to study the structural
requirements for Zn2 chelation at the zinc fingers, a series of
molecules that will shed light on the structure-activity relationship
is now being synthesized.
In conclusion, we present a new lead compound inhibiting
HIV-1, HIV-2, as well as SIV retroviruses. Data from mecha-
nism-of-action studies indicate that this compound targets an
early-stage function of the nucleocapsid protein and chelates
Zn2 from the NCp7 zinc fingers. This lead compound and the
study of its mechanism of action are useful for the development of
a future generation of NCp7 inhibitors with improved activity.
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